I'm LongbridgeAI, I can summarize articles.SPDR S&P Biotech (XBI.US) ended the week at $156.2, down 4.65% and lagging the S&P 500 by about 3.85 percentage points. The session flow was choppy and back-loaded: Tuesday touched the week’s high of $163.43, Wednesday faded, Thursday slid to the week’s low of $155.82, and Friday closed near that level at $156.2. The weekly range was 4.73%. Average daily volume of about 8.0m shares came in roughly 5.79% below the 60-day median, so turnover stayed modest.
The Week
SPDR S&P Biotech (XBI.US) ended the week at $156.2, down 4.65% and lagging the S&P 500 by about 3.85 percentage points. The session flow was choppy and back-loaded: Tuesday touched the week’s high of $163.43, Wednesday faded, Thursday slid to the week’s low of $155.82, and Friday closed near that level at $156.2. The weekly range was 4.73%. Average daily volume of about 8.0m shares came in roughly 5.79% below the 60-day median, so turnover stayed modest.
Sector News
Biotech news flow was heavy this week, with attention centred on Roivant Sciences’ PHocus trial data and the ratings that followed, while Revolution Medicines’ RASONQUE approval and Veru’s positive preclinical update in resistant pancreatic cancer kept the space in focus. At the money-flow level, the latest session showed large lots acting as net buyers while small and medium lots were net sellers. No material corporate filings emerged beyond a routine N-CEN update.
The Week Ahead
Macro data dominates the calendar: the New York Fed manufacturing index lands on 15 September, followed by retail sales, import prices and the NAHB housing market index on 16 September. Headline retail sales carried a prior of 5.01%, while retail sales ex-autos printed -0.3% previously against a 0.6% forecast. If the figures reinforce the market’s rate-hike pricing, rate-sensitive biotech could stay under pressure.
In Short
XBI.US fell 4.65% even as a string of positive clinical developments and buy ratings crossed the tape, which suggests individual catalysts were not enough to offset the broader pullback in risk appetite. The latest session showed large-lot buying against small-lot selling, and with macro data and the Fed meeting around the corner, the near-term tone remains driven by rate expectations. The trade to watch is whether retail sales and inflation clues confirm or weaken the hike narrative, and whether that gives biotech a chance to stabilise.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.